Open Access<p>Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier</p>
Author(s) -
Xiaoqi Wang,
Wenxing Mao,
Zhi Wang,
Xinrui Li,
Yaokun Xiong,
Hongjin Lu,
Xiuzhen Wang,
Haoyuan Yin,
Xiang Cao,
Hongliang Xin
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s258699
Subject(s) - nanocarriers , brain metastasis , doxorubicin , medicine , in vivo , targeted drug delivery , targeted therapy , drug delivery , pharmacology , cancer research , metastasis , blood–brain barrier , chemotherapy , drug , cancer , biology , materials science , central nervous system , nanotechnology , microbiology and biotechnology
Currently, the treatment of brain metastases from non-small cell lung cancer (NSCLC) is rather difficult in the clinic. A combination of small molecule-targeted drug and chemo-drug is a promising therapeutic strategy for the treatment of NSCLC brain metastases. But the efficacy of this combination therapy is not satisfactory due to the blood-brain barrier (BBB). Therefore, it is urgent to develop a drug delivery system to enhance the synergistic therapeutic effects of small molecule-targeted drug and chemo-drug for the treatment of NSCLC brain metastases.